NCT01618747
Completed
Not Applicable
A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma
ConditionsGlioblastoma Multiforme
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Glioblastoma Multiforme
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 20
- Primary Endpoint
- Progression-free survival at 6 months
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults patients, \>/= 18 years of age
- •Histologically confirmed glioblastoma multiforme in first or second relapse
Exclusion Criteria
- •Patients not qualifying for Avastin treatment as per local label
Outcomes
Primary Outcomes
Progression-free survival at 6 months
Time Frame: approximately 3 years
Secondary Outcomes
- Progression-free survival(approximately 3 years)
- Time to disease progression(approximately 3 years)
- Duration of objective response(approximately 3 years)
- Overall survival(approximately 3 years)
- Safety: Incidence of adverse events(approximately 3 years)
Similar Trials
Completed
Phase 3
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionInfluenza, HumanNCT01527110GlaxoSmithKline21
Terminated
Not Applicable
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical PracticeRheumatoid ArthritisNCT02616328Hoffmann-La Roche8
Completed
Not Applicable
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesChronic Lymphocytic LeukemiaNCT02915224Hoffmann-La Roche50
Completed
Phase 3
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyRelapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum SensitiveNCT03534453AstraZeneca229
Not yet recruiting
Phase 1
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45